Drug
Daclizumab
Daclizumab: highest development phase Post-Market, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Daclizumab NCT00048165 | Post-Market | Heart Transplantation |
Latest
No recent events.
Follow Daclizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.